Currently, IONS has a robust portfolio of treatments for rare and prevalent diseases. This includes Spinraza for spinal muscular atrophy, Qalsody for SOD1-ALS, and its recently FDA-approved ...

Here are four drug and biotech stocks, ARQT, MESO, MNPR and KOD, which have more than doubled in 2024 with room for further growth in 2025.

In the quest for improved health and vitality, dietary supplements have become a popular choice among individuals seeking to ...

BMY has had a robust H1'24 stock price performance, aided by the July/ August 2024 market rotation and the US FDA timely ...

In the quest for better health and vitality, particularly as we age, dietary supplements have become an integral part of many ...

We recently compiled a list of the 10 Stocks That Will Make You Rich In 2025. In this article, we are going to take a look at ...

Earlier this year, scientists stumbled upon a potential new treatment for hereditary-patterned baldness, the most common ...

The obesity medication Zepbound can be used on-label to treat obstructive sleep apnea in adults with obesity, the FDA ...

The Phase 1 trial is set to begin in the first quarter of 2025, with data expected in the second quarter of 2025. MIRA plans to initiate a Phase 2a proof-of-concept study in Q4 2025, focusing on ...

which could accelerate the approval process. The ongoing engagement with the FDA and the robust data, including over 500 years of patient exposure, highlight the product’s potential in ...

The FDA's approval is based on data from two trials ... driven by surging interest in artificial intelligence and the robust demand for its AI-centric chips across various industries.

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality ...